Gefitinib and erlotinib are commercially available epidermal growth factor receptor tyrosine
kinase inhibitors (EGFR-TKIs) that are widely used for the treatment of non-small-cell lung …

Introduction Gefitinib and erlotinib have minor differences in their chemical structures, and
thus it remains unclear whether the hepatotoxicity induced by one compound is affected by …

Objective. Gefitinib often induces liver damage. A few reports have described that the
subsequent administration of erlotinib was associated with less hepatotoxicity, but the safety …

Gefitinib and erlotinib are selective epidermal growth factor receptor-tyrosine kinase (EGFR-
TK) inhibitor. They are approved for the treatment of adults with locally advanced or …

INTRODUCTION: Hepatotoxicity secondary to gefitinib, an oral tyrosine kinase inhibitor (TKI)
against the epidermal growth factor receptor (EGFR), is under-appreciated, even though it …

Drug-induced liver injury (DILI) is a common occurrence in clinical practice in the present
era because of frequent use of drugs and increase in patients who have increased …

Background: Although epidermal growth factor receptor (EGFR)-specific tyrosine kinase
inhibitors (TKIs) are widely used in the management of advanced non-small cell lung cancer …

Gefitinib has come to be the most widely used epidermal growth factor receptor‑tyrosine
kinase inhibitor in the treatment of advanced non‑small cell lung cancer (NSCLC) in Asian …

Gefitinib blocks epidermal growth factor receptor autophosphorylation and subsequently the
signal transduction pathways implicated in proliferation, metastasis, invasion, and …

Gefitinib and erlotinib are first-generation small molecular inhibitors of EGFR tyrosine kinase
activity. To the best of our knowledge, to date, two reports have stated that patients with …